Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Prolia, Xgeva
Synonyms :
AMG-162
Class :
Antineoplastics and Monoclonal antibody
Brand Name :
Prolia, Xgeva
Synonyms :
AMG-162
Class :
Antineoplastics and Monoclonal antibody
120
mg
Solution
Subcutaneous (SC)
every 4 weeks
On days eight and 15-give two additional 120 mg dose
Wyost, an interchangeable biosimilar of Xgeva, receives FDA approval on March 5, 2024 (denosumab-bddz).
Prolia only (Adults)
Osteoporosis
60mg subcutaneously every six months
Aromatase Inhibitor Induced Bone Loss
60mg subcutaneously every six months
Androgen Deprivation Induced Bone Loss
60mg subcutaneously every six months
Glucocorticoid Induced Osteoporosis
60mg subcutaneously every six months
Xgeva only (Adults)
Skeletal-Related Events
120mg subcutaneously every four weeks
Giant cell tumor
120mg subcutaneously every four weeks
On days eight and 15-give two additional 120 mg dose
Hypercalcemia of malignancy
120mg subcutaneously every four weeks
On days eight and 15-give two additional 120 mg dose
<13 years or <45kg: :
Safety and efficacy not established
13-17 years (≥45kg): 120 mg subcutaneously every 4 Weeks; give two additional 120 mg doses on Days 8 and 15
it may enhance the immunosuppressive effect of Immunosuppressants
it may enhance the immunosuppressive effect of Immunosuppressants
it may enhance the immunosuppressive effect of Immunosuppressants
it may enhance the immunosuppressive effect of Immunosuppressants
it may enhance the immunosuppressive effect of Immunosuppressants
may have an increased immunosuppressive effect when combined with denosumab
may have an increased immunosuppressive effect when combined with denosumab
may have an increased immunosuppressive effect when combined with denosumab
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
may have an increased immunosuppressive effect when combined with corticosteroids
denosumab: they may increase the immunosuppressive effect of immunostimulants
denosumab: they may increase the immunosuppressive effect of immunostimulants
denosumab: they may increase the immunosuppressive effect of immunostimulants
denosumab: they may increase the immunosuppressive effect of immunostimulants
denosumab: they may increase the immunosuppressive effect of immunostimulants
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may enhance the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressive agents
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
may increase the immunosuppressive effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
influenza virus vaccine trivalent recombinant
May diminish the effects of each other by pharmacodynamic antagonism
influenza virus vaccine quadrivalent adjuvanted
May diminish the effects of each other by pharmacodynamic antagonism
Immunosuppressive effects enhance the other's impact and infection risk
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effect of immunosuppressants
in combination with ofatumumab, denosumab increases the risk of adverse events.
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
may increase the toxic effects when combined
may increase the risk or severity of adverse effects when combined
may enhance the immunosuppressive effects of each other
may decrease the effects of receptor binding competition
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
It may enhance the effect when combined with beclomethasone, inhaled by immunosuppressive effects
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
When mometasone furoate is used together with denosumab, this leads to enhanced risk or seriousness of adverse outcomes
when both drugs combine there will be the increased risk of infection.
when both the drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
interaction increases the risk of excessive immunosuppression
may enhance immunosuppressive effects of daunorubicin
when both drugs are combined, there may be an increased risk or severity of adverse effects
risk of severe infection due to immunosuppressive effects
increased risk of serious infection due to impaired immune system
increased risk of serious infection due to impaired immune system
increased risk of serious infection due to impaired immune system
may enhance excessive immunosuppressant effects
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
may enhance immunosuppressive effects of idarubicin
It may enhance the adverse effects when combined with sotrovimab
the activity of the anthrax vaccine can be reduced when used in combination with denosumab
it increases the effect of immunosuppressive agents
it increases the effect of immunosuppressive agents
it increases the effect of immunosuppressive agents
it increases the effect of immunosuppressive agents
it increases the effect of immunosuppressive agents
The immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be increased by denosumab
The immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be increased by denosumab
The immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be increased by denosumab
The immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be increased by denosumab
The immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be increased by denosumab
it increases the effect of immunosuppressants
Frequency defined:
>10% (Prolia)
Back pain (34.7%)
Extremity pain (11.7%)
>10% (Xgeva)
Fatigue/asthenia (45%)
Hypophosphatemia (32%)
Nausea (31%)
Dyspnea (21%)
Diarrhea (20%)
Hypocalcemia (18%)
Cough (15%)
Headache (13%)
Be cautious with patients suffering from hypersensitivity and hypocalcemia.
Pregnancy consideration: The drug is not recommended during pregnancy as it may affect the fetus
Pregnancy category: C
Lactation: The release of the drug into the human breastmilk is unknown
Pregnancy category:
Patient information leaflet
Generic Name: denosumab
Pronounced: [den-OH-sue-mab]
Why do we use denosumab?
Denosumab treats osteoporosis in postmenopausal women and men at high risk of fracture.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
